Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

United States — Food and Drug Administration & F. Hoffmann-La Roche — Genentech

9 shared events · Importance 4 · Last updated Sep 10, 2026

Importance
4
Shared Events
9
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
95
Tech
United States — Food and Drug Administration: The United States — Food and Drug Administration>>> accepted F. Hoffmann-La Roche — Genentech>>>'s New Drug Application for giredestrant under Priority Review, setting a decision date for approval by November 30, 2026.
F. Hoffmann-La Roche — Genentech: As a member of the Roche Group, F. Hoffmann-La Roche — Genentech>>> developed giredestrant and had its New Drug Application accepted by the United States — Food and Drug Administration>>> for priority review, indicating potential for a new standard-of-care in breast cancer treatment.
Jun 02, 2026 · 6 articles
53
Regulatory
United States — Food and Drug Administration: The FDA previously approved Signatera as a companion diagnostic for adjuvant Tecentriq, providing a regulatory precedent that supports the Japan submission.
F. Hoffmann-La Roche — Genentech: F. Hoffmann-La Roche — Genentech's Tecentriq (atezolizumab) is the therapy guided by Signatera in this CDx application. Positive trial data could boost Tecentriq's use in adjuvant bladder cancer.
Aug 05, 2026 · 7 articles
52
Business
United States — Food and Drug Administration: The FDA granted IND clearance for HM17321 in November 2025, enabling the Phase 1 trial. Its regulatory role is crucial for the drug's development.
F. Hoffmann-La Roche — Genentech: F. Hoffmann-La Roche — Genentech gains exclusive rights to a promising obesity therapy, expanding its pipeline. The deal involves significant financial commitment but offers potential long-term returns.
Jul 20, 2026 · 7 articles
50
Regulatory
United States — Food and Drug Administration: The FDA granted Priority Review and will decide on approval by 10 January 2027, making it the key regulatory gatekeeper for the drug's U.S. launch.
F. Hoffmann-La Roche — Genentech: F. Hoffmann-La Roche — Genentech, Roche's fully owned U.S. subsidiary, would commercialize Enspryng in the United States if the MOGAD indication is approved.
Sep 09, 2026 · 6 articles
42
Regulatory
United States — Food and Drug Administration: The FDA granted approval for the phase II trial, acting as the regulatory authority enabling the clinical development of ziresovir in the U.S.
F. Hoffmann-La Roche — Genentech: F. Hoffmann-La Roche — Genentech, as a partner of ArkBio, may benefit from the progress of ziresovir through their strategic collaboration.
Jul 20, 2026 · 6 articles
37
Regulatory
United States — Food and Drug Administration: The FDA previously approved Signatera as a companion diagnostic for adjuvant atezolizumab in MIBC, a precedent referenced in the Japanese approval.
F. Hoffmann-La Roche — Genentech: F. Hoffmann-La Roche — Genentech's atezolizumab (Tecentriq) is the therapy that Signatera guides, so the approval supports companion diagnostic use alongside its drug in Japan.
Sep 22, 2026 · 6 articles
17
Tech
United States — Food and Drug Administration: The FDA has granted paxalisib various designations in other indications; this event does not involve new regulatory actions, but future trials may require FDA interaction.
F. Hoffmann-La Roche — Genentech: F. Hoffmann-La Roche — Genentech originally licensed paxalisib to Kazia; the drug's progress may reflect positively on F. Hoffmann-La Roche — Genentech's early research, but F. Hoffmann-La Roche — Genentech has no direct involvement in this event.
Jul 20, 2026 · 7 articles
14
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration has granted various designations to MiNK Therapeutics' programs and is involved in the approval pathway for its Fabry gene therapy.
F. Hoffmann-La Roche — Genentech: F. Hoffmann-La Roche — Genentech has licensed MiNK Therapeutics' STAC-BBB platform for neurological targets, indicating a past business relationship that could be affected by Sangamo's strategic review.
Jun 08, 2026 · 7 articles
10
Business
United States — Food and Drug Administration: The FDA has granted designations to paxalisib, and the offering funds clinical trials that may lead to regulatory submissions. No direct financial impact.
F. Hoffmann-La Roche — Genentech: F. Hoffmann-La Roche — Genentech licensed paxalisib to Kazia in 2016. The offering funds further development of this asset, potentially leading to future royalties or milestones for F. Hoffmann-La Roche — Genentech.
Jul 20, 2026 · 22 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States — Food and Drug Administration and F. Hoffmann-La Roche — Genentech interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.